This trial is evaluating whether Colorectal Health Research Champions will improve 2 primary outcomes in patients with Cancer of Colon. Measurement will happen over the course of 4 months.
This trial requires 400 total participants across 2 different treatment groups
This trial involves 2 different treatments. Colorectal Health Research Champions is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Individuals with both a low PSA level and previous endoscopic treatment of colon polyps have a relatively high risk of developing [colon cancer](https://www.withpower.com/clinical-trials/colon-cancer). Individuals with colorectal cancer should have a repeat PSA test at 6mo. The risks of developing cancer of colon are similar for both men and women.
Most cases of [colon cancer](https://www.withpower.com/clinical-trials/colon-cancer) that are detected in people over 65 are adenomas and not cancers. This is probably because they are detected later than cancers of the rectum and anus. Older age is often a good indicator of detecting colon cancer, but this cancer is also related to a high dietary fat and low fibre diet. Smoking is also a risk factor. Some cases are detected because they cause bleeding or pain and hence they are identified during screening.
The development of colorectal cancer may be caused by a variety of factors including hereditary conditions and diets. Tobacco use is one of the greatest risk factors for colon cancer. The diagnosis of colon cancer may cause the person to question normal values of diet, hygiene, exercise, and colonoscopy.
The treatments that treat people with [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer) can be classified into specific groups, namely chemotherapy, radiation therapy, and surgery. While chemotherapy and radiation therapy have a significant impact in terms of a cure rates, surgical intervention plays a major role by making the treatment effective even in a case of local-recurrence for people with colorectal cancer. It can be seen in statistics that people, as they get older, are suffering from a higher rates of colorectal cancer that results in a better survivability rate on a long-term period despite of the risks incurred in a cancer surgeries. [cite (1) Schillberg, P. (2006).
About 33,300 new cases of colon cancer are expected to be diagnosed in the United States in 2000, which equals 8.7% of all diagnoses of colorectal cancer. This would be up from 11.6% of colorectal cancer diagnoses in 2000, and is 2.8% higher than the proportion attributed to colon cancer. Over the next 20 years, we expect to have an annual increase in colorectal cancer of 9.8% and a 4.2% increase in colon cancer-related deaths. From 1979-1999 the number of new cases of colorectal cancer increased 8.
Findings from a recent study showed that patients can expect a cure from treatment of colon cancer in nearly three quarters of matched cohort cases. However our results do not show that any patient can expect cure with either surgery or chemotherapy in the absence of chemotherapy or surgery.
There is a very clear survival advantage for patients with left-sided colorectal cancer who undergo resections for curative purposes. Survival time of patients who underwent right-sided resections was significantly shorter at the end of the study period.
There is no evidence that CHRC are typically used in combination with any other treatments in clinical practice, but it is not uncommon to use CHRC as part of an integral approach in a patient's management.
Current clinical trials have found that immunostimulants are effective in treating [cancer of the colon]. Ongoing trials have confirmed previous findings, and several compounds have shown efficacy when compared with placebo in well-defined subgroups with well-characterized prognostic factors after resection of primary tumours. Although there are some disadvantages to therapeutic use, the results of these clinical trials are encouraging and may lead to a shift in thinking from palliative care towards curative care.
The findings of this study indicate that, in terms of the characteristics of this sample of health professionals, the work of community health champions varied considerably from one individual to another but that, despite this variability, the CHCs were generally able to function effectively as a resource for the study.
Most respondents to this study preferred to complete clinical trial reporting guidelines in order to minimize the impact that potential side effects might have on clinical trial conclusions on their treatment. Physicians and participants in the current study have a keen interest in being informed of these side effects, but they are not aware of all the side effects associated with colorectal cancer treatments. The fact that they are more widely accessible, such as in reporting guidelines, may be one reason why colorectal cancer is a disease whose treatment side effects are poorly understood. Efforts to increase the number of participants using the reporting guideline are needed.